Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2023
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 November 2021
Vandetanib for treating medullary thyroid cancer (TA550)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2018
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2018
Cabozantinib for treating medullary thyroid cancer (TA516)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2018
Pralsetinib for thyroid cancer [ID4018]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC